Analyst Price Targets — CLLS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 28, 2026 7:36 am | Lukas Shumway | Barclays | $9.00 | $3.63 | StreetInsider | Barclays Starts Cellectis (CLLS) at Overweight |
| October 20, 2025 10:45 am | Nick Abbott | Wells Fargo | $4.00 | $3.98 | TheFly | Cellectis price target raised to $4 from $3 at Wells Fargo |
| October 17, 2025 9:23 am | Gena Wang | Barclays | $8.00 | $4.52 | TheFly | Cellectis price target raised to $8 from $4 at Barclays |
Latest News for CLLS
EMERYVILLE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Prolynx, a biotechnology company developing a next-generation portfolio of ultra-long-acting medicines for obesity and related metabolic conditions, today announced two additions to its executive leadership team: Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer.
NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, presents final Phase 1 data from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T therapy, in patients with relapsed/refractory B-cell acute…
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its…
PARIS, June 03, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the capital Total number of voting rights 05/31/2026 100,691,658 106,134,467 For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CLLS.
Senate Trading
No Senate trades found for CLLS.
U.S. House Trading
No House trades found for CLLS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.